Growing up with parenteral nutrition
Paul, the four-legged therapist
The History of Dialysis
’Remain true to your ideals’
Serving patients in Swaziland
Using protons to take on cancer
A little heart at the center of a complex surgery
On duty in disaster zones
More ‘Quality of Life’ in clinics
Ready to help the littlest ones
"I want to help others, so they won’t give up"
From a local pharmacy to a global corporation
Group Outlook 2019
In 2019, we expect to increase Group sales1 by 3% to 6% in constant currency. We project Group net income2,3 to increase by ~ 0% in constant currency.
Fresenius Group Overview
- The Health Care Group
-
Stories
-
![]()
Growing up with parenteral nutrition
-
![]()
Paul, the four-legged therapist
-
![]()
The History of Dialysis
-
![]()
’Remain true to your ideals’
-
![]()
Serving patients in Swaziland
-
![]()
Using protons to take on cancer
-
![]()
A little heart at the center of a complex surgery
-
![]()
On duty in disaster zones
-
![]()
More ‘Quality of Life’ in clinics
-
![]()
Ready to help the littlest ones
-
![]()
"I want to help others, so they won’t give up"
-
![]()
From a local pharmacy to a global corporation
-
- Investors
-
Media
![]()
Contact
Matthias Link
Vice President Corporate Communications
T: +49 (0) 6172 608-2872
matthias.link@fresenius.com - Careers
Outlook
- Investors
- Strategy & Outlook
- Outlook
-
Share Price
Data is delayed by 15 minutes.
Share Price Information -
Related Links
-
Library
-
Event
May 02, 2019 - 01:30 PM | Bad Homburg, Germany
Conference Call Q1 2019, Fresenius
-
FAQ
| Targets 2019 | Fiscal year 20184 | |
| Fresenius Group | ||
| Sales growth (in constant currency) | 3% – 6%5 | € 33,009 million |
|
Net income2 growth |
~0%6 | € 1,872 million |
| Fresenius Medical Care | ||
|
Sales growth (in constant currency) |
3% – 7%6 | € 16,026 million |
| Net income7 growth (in constant currency) | -2% – +2%6 | € 1,341 million |
| Fresenius Kabi | ||
| Sales growth (organic) | 3% – 6%6 | € 6,544 million |
| EBIT growth (in constant currency) | 3% – 6%6 | € 1,139 million |
| Fresenius Helios | ||
| Sales growth (organic) | 2% – 5%6 | € 8,993 million |
| EBIT growth | -5% – -2%6 | € 1,052 million |
| Fresenius Vamed | ||
| Sales growth (organic) | ~10%6 | € 1,688 million |
| EBIT growth | 15% – 20%6 | € 110 million |
- 1 Base 2018: €33,009 million; 2018 adjusted for divestitures of Care Coordination activities at FMC (H1 / 18); 2019 adjusted for IFRS 16 effects, excluding effects from pending acquisition of NxStage by FMC
- 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
- 3 Base 2018: € 1,872 million; 2018 before special items and adjusted for divestitures of Care Coordination activities at FMC (H1 /18); 2019 before special items (before transaction-related expenses, expenses associated with the cost optimization program at FMC, revaluations of biosimilars contingent liabilities), adjusted for IFRS 16 effects, excluding effects from pending acquisition of NxStage by FMC
- 4 Before special items and after adjustments
- 5 Adjusted for effects of IFRS 16, excluding effects from pending acquisition of NxStage by FMC
- 6 Before special items (before transaction-related expenses, expenses associated with the cost optimization program at FMC, revaluations of biosimilars contingent liabilities), adjusted for IFRS 16 effects, excluding effects from pending acquisition of NxStage by FMC
- 7 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
- As of December 31, 2018
Contact us
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com
Contact
